secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001193125-23-204493
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 2.01, 3.02, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology acquires Pionyr in all-stock deal, receives ~$43M net cash
-------------------------------------------------------------------------

- Ikena issued 1.8M common shares and 4.2M Series A convertible preferred shares at $7.15/share for all of Pionyr.
- Pionyr contributed ~$43M net cash; Ikena to use funds to accelerate IK-930 and IK-595 clinical programs.
- Pionyr shareholders (including Gilead Sciences) hold ~12% of Ikena post-deal; management and board unchanged.
- CVRs grant Pionyr holders 50% of net proceeds from any monetization of Pionyr legacy assets within two years.
- Ikena expects initial IK-930 clinical data in 2023 and IK-595 IND filing later in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/d469204d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-204493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer